Results for tag: "Orkambi"

Orkambi is a brand of respiratory drug used to treat cystic fibrosis (CF). It is a combination of two drugs, lumacaftor and ivacaftor, which work together to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The drug is approved for use in patients aged 12 and older who have two copies of the F508del mutation in the CFTR gene. Orkambi is the first drug to target the underlying cause of CF, and has been shown to improve lung function, reduce exacerbations, and improve quality of life. The Orkambi market is highly competitive, with several companies offering similar products. These include Vertex Pharmaceuticals, which manufactures and markets Orkambi, as well as other CF treatments; Gilead Sciences, which markets the combination drug Cayston; and Novartis, which markets the combination drug Kalydeco. Other companies in the market include Genentech, which markets the combination drug Symdeko, and AstraZeneca, which markets the combination drug Symkevi. Show Less Read more